Hepatitis C

Principles of GI for the NP and PA

Aug. 10, 2018

Hear from the experts as they provide you with critical updates on treating and managing patients with a variety of GI disorders.

HCV in pregnant women on rise

March 8, 2018

Increased risk of HCV infected infants.

Pharmacists Could Play Bigger Role in Working with Hepatitis C Patients

Feb. 22, 2018

Model used in VA health care system could be translated to other settings.

Attend the AGA Postgraduate Course for Practical, Take Home Information

Feb. 12, 2018

Join us on June 2-3 in Washington, D.C. This course is held in conjunction with Digestive Disease Week® (DDW) 2018.

Medicaid Skimps on Hepatitis C Treatment in Many States

Feb. 8, 2018

Report finds restrictions based on liver disease severity, sobriety and type of provider.

Image Challenge: Cullen's Sign

Jan. 22, 2018

What caused a 56-year-old man with a previous history of cirrhosis to present with a large volume of ascites and periumbilical ecchymosis?

2018 AGA Postgraduate Course Resources

Jan. 17, 2018

Pre-order resources from the course when you register.

Save the Date: 2018 AGA Postgraduate Course

Jan. 11, 2018

This year’s course will take place on June 2 and 3, 2018, in Washington, D.C.

Compendium of AGA 2017 Clinical Guidance

Dec. 21, 2017

Are you up-to-date on AGA's latest clinical guidance?

Digestive Disease Week® (DDW)

Dec. 19, 2017

Digestive Disease Week® (DDW) is the premier meeting for the GI professional. Every year it attracts approximately 15,000 physicians, researchers and academics from around the world who desire to stay up-to-date in the field.

Community Health Clinics Evolving HCV Programs

Dec. 14, 2017

Increasing importance in treating high-risk populations as access to care improves.

Building Foundations Among Payers & Providers for Collaborative Care in HCV & HIV

Dec. 7, 2017

In this video, leading experts in HCV, HIV, and managed care engage in a crossfire panel discussion on key challenges, considerations and solutions for improving patient management, and appropriate access to HCV and HIV therapies.

Translating Basic Science Into Clinical Application

Dec. 7, 2017

The CMGH editors summarize five recently accepted studies in four sentences or less.

Case Clinic 3: A 29-Year-Old Caucasian Man With a History of Injected Drug Use

Nov. 30, 2017

Clinicians are challenged to determine the optimal approach to treatment, which involves selecting an appropriate treatment regimen based on viral genotypes and subtypes and employing efficacy protocols.

Experts Update HCV Treatment and Care Guidelines

Nov. 9, 2017

Revision adds newly approved treatments and recommendations for special populations.

Case Clinic 2: A 49-Year-Old Man With a History of Alcohol Consumption

Nov. 9, 2017

This case highlights the importance screening for HCV and retaining patients in care once the diagnosis is established. Response to treatment in African Americans and strategies for overcoming common barriers to treatment also are reviewed.

Why the VA is So Successful Tackling HCV

Oct. 26, 2017

VA experts tell how they get high-risk patients engaged, nationally.

Analysis of Hepatitis C Virus Particle Heterogeneity in Immunodeficient Human Liver Chimeric fah-/- Mice

Oct. 22, 2017

Our work indicates that the heterogeneity in buoyant density of infectious HCV particles evolves over the course of infection and can be influenced by diet.

Native Americans Have Highest HCV Rates

Oct. 12, 2017

Treatment for HCV challenging due to the limited Indian Health Services (IHS) funding.

Duration of Hepatitis C Virus Therapy

Oct. 11, 2017

Shorter duration therapy reduces treatment costs and may also improve adherence. How short can therapy be and who would qualify?

Spotlight on Fellow-Led Quality Improvement Projects

Oct. 3, 2017

These 19 projects presented at DDW® 2017 showcase the extensive work being done by fellows to improve the quality of care provided to GI patients.

Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents

Oct. 1, 2017

Among HCV-infected patients treated with DAAs, SVR is associated with a considerable reduction in the risk of HCC; however, the risk for HCC remained high in patients with cirrhosis at the time of SVR.

Is HCV Drug Development Nearing Its End?

Sept. 28, 2017

Two new FDA approvals fill medical gaps, but access to treatment remains a challenge.

Case Clinic 1: A 61-Year-Old Woman Previously Treated for HCV Genotype 1a

Sept. 28, 2017

This case highlights how findings of resistance and advanced fibrosis affect HCV management as well as the importance of post-treatment surveillance for hepatocellular carcinoma.